Protagonist Therapeutics, Inc.
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $7.26B |
| Revenue | $74M |
| Net Income | $-115M |
| Total Assets | $697M |
| Net Assets | $655M |
| Employees | 132 |
| Value | |
| P/B | 11.07x |
| P/S | 98.00x |
| FCF Yield | -1.60% |
| Profitability | |
| ROE | -17.50% |
| ROA | -16.45% |
| Op. Margin | -192.36% |
| Revenue Growth | 99.03% |
| Earnings Growth | -147.29% |
| Financial Health | |
| Debt Ratio | 6.41% |
| Total Debt | $10M |
| FCF | $-116M |
| Cash | $194M |
| Current Ratio | 17.76x |
| Performance | |
| 1Y Return | 109.31% |
| 1M Return | 14.73% |
| From 52W High | -1.42% |
| 1Y MDD | -16.38% |
| Trading | |
| Volume | 1,273,721 shares |
| Trading Value | $144M |
| Per Share | |
| EPS | $-2.05 |
| BPS | $9.67 |
Company Info
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.